Dr.Jay Sheth, S18167
Aim:To evaluate 1-year outcomes in PCN eyes treated with PRN Anti-VEGF monotherapy (IVR/IVA;Group1) or in combination with PDT(Group2)
Method:Retrospective analysis of 9 PCN eyes(Group1: 6; Group2: 3) who were evaluated for changes in BCVA, subfoveal choroidal thickness(SFCT), intraretinal fluid(IRF), subretinal fluid(SRF) & PED dimensions(height,base) from baseline at a mean follow-up of 23.8 ± 13.2 months
Result:Compared with baseline, significant improvement was seen in BCVA(p=0.02), SFCT(p=0.009), & PED(p=0.02) & SRF(p=0.01) height respectively. The mean number of injections was 5 ± 2.8. 80% & 44.4% of eyes had complete resolution of IRF & SRF respectively. Improvement was seen in PED width & CMT although not significantly. No significant difference was noted between the two groups
Conclusion:In real-world scenario, improvement in BCVA & micromorphic OCT parameters with reduction in CT is noted in PCN eyes treated with either PRN anti-VEGF monotherapy or in combination with PDT
Leave a Comment